Bioactive
peptide was produced by fusion to rice
prolamins in transgenic rice seeds. Their accumulation levels were affected by their deposition sites and by compensatory rebalancing between
prolamins within PB-Is.
Peptide immunotherapy using analogue
peptide ligands (APLs) is one of promising treatments against
autoimmune diseases. Use of
seed storage protein as a fusion carrier is reasonable strategy for production of such small size bioactive
peptides. In this study, to examine the efficacy of various rice
prolamins deposited in ER-derived
protein bodies (PB-Is), the APL12 from the
Glucose-6-phosphate isomerase (GPI325-339) was expressed by fusion to four types of representative
prolamins under the control of the individual native promoters. When the 14 and 16 kDa Cys-rich
prolamins, which were localized in middle layer of PB-Is, were used for production of the APL12, they highly accumulated in transgenic rice seeds (~ 200 µg/grain). By contrast, fusion to the 10 and 13 kDa
prolamins, which were localized in the core and outermost layer of PB-Is, resulted in lower levels of accumulation (~ 40 µg/grain). These results suggest that accumulation levels were highly affected by their deposition sites. Next, when different
prolamin/APL12 fusion
proteins were co-expressed to increase accumulation levels, they could not be increased so much as their expected additive levels. High accumulation of one type
prolamin/APL12 led to reduction of other type(s)
prolamin/APL12 to maintain the limited amounts of
prolamins that can be deposited in PB-Is. Moreover, suppression of endogenous seed
proteins by RNA interference also did not significantly enhance the accumulation levels of
prolamin/APL12. These findings suggest that there may be compensatory rebalancing mechanism that controls the accumulation levels of
prolamins deposited within PB-Is.